AstraZeneca worldwide

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

AstraZeneca in Kazakhstan

The representative office of AstraZeneca in Kazakhstan was opened in 2007. The company currently employs approximately 200 employees in various regions of the country: Almaty, Astana, Karaganda, Shymkent, Aktobe, Ust-Kamenogorsk, Uralsk, etc. Currently, 24 AstraZeneca drug products have been registered in Kazakhstan in the following therapeutic areas: oncology, respiratory and autoimmune diseases, cardiovascular diseases, metabolic disorders, and rare diseases. By 2026, the company plans to introduce over 15 new products to the Republic market. In September 2023, AstraZeneca Kazakhstan LLP (Limited Liability Partnership) was registered in Kazakhstan.

AstraZeneca cooperates with the Ministry of Health of the Republic of Kazakhstan to implement a number of large-scale projects to improve the quality and accessibility of innovative medicine for all patients in the Republic. The company is a member of AIPM, Eurobak, and acts as a regular speaker of the National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken".

AstraZeneca initiates industry discussion platforms in healthcare. Supported by AstraZeneca, Business Sweden roundtables are held regularly with the participation of the Ministry of Health of Kazakhstan and the Embassy of Sweden in Kazakhstan. Being an Anglo-Swedish company, AstraZeneca intends to initiate the development of discussion platforms, including those with the Embassy of the United Kingdom.

AstraZeneca gives particular emphasis to disease diagnosis improvement and clinical trial development projects in the Republic of Kazakhstan.

AstraZeneca in Uzbekistan

Since 2021, AstraZeneca has been present in Uzbekistan. The company operates through local distributors. Currently, 9 AstraZeneca drug products have been registered in Uzbekistan in the following therapeutic areas: oncology, oncohematology, cardiovascular diseases, endocrinology, asthma, and chronic obstructive pulmonary disease. In the next 3–5 years, the company plans to introduce new innovative drugs to the Uzbekistan market, including for the treatment of lung, breast, gastrointestinal cancers, and orphan diseases.

AstraZeneca actively cooperates with the healthcare regulatory agencies and the healthcare community in Uzbekistan. AstraZeneca plans to implement several complex projects with the Ministry of Health of Uzbekistan and national republican research and practical centers. These initiatives include screening projects for chronic diseases such as chronic heart failure, and long-term drug supply projects in oncology and oncohematology.

AstraZeneca is a member of the Association of foreign pharmaceutical companies and manufacturers, and Eurouz. The company regularly participates in the largest national pharmaceutical forums in Uzbekistan.

In addition to bringing innovative drugs to market, AstraZeneca actively develops the local expert community by initiating events for regulatory agencies and healthcare professionals in Uzbekistan. For example, AstraZeneca organized a seminar on the evaluation of healthcare technologies with the participation of leading experts from the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, Federal State Budgetary Institution. Being an Anglo-Swedish company, AstraZeneca intends to continue developing discussion platforms, including those with the Embassies of Sweden and the United Kingdom in Uzbekistan.

AstraZeneca worldwide official website

AstraZeneca Russia official website

AstraZeneca Kazakhstan official website